| Prevention of Acute Upper Respiratory Infections by Consumption of Catechins in Healthcare Workers: A Randomized, Placebo-Controlled Trial 2019 · high-catechin group · Healthy adult healthcare workers; mean age 43.2 years, 76.9% female across the analysis population. | 60 mg | 12 weeks | 91 |
| Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus 2015 · Poly E 600 mg BID · Adults aged 18 years or older with Barrett's esophagus, with or without low-grade dysplasia | 1.2 g | 26 weeks | 20 |
| Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer 2012 · Poly E 400 mg EGCG dose level · Women aged 21–65 with a history of resected stage I–III hormone receptor-negative breast cancer and no evidence of disease | 800 mg | 26 weeks | 16 |
| Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer 2012 · Poly E 600 mg EGCG dose level · Women aged 21–65 with a history of resected stage I–III hormone receptor-negative breast cancer and no evidence of disease | 1.2 g | 26 weeks | 11 |
| Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus 2015 · Poly E 400 mg BID · Adults aged 18 years or older with Barrett's esophagus, with or without low-grade dysplasia | 800 mg | 26 weeks | 7 |
| Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus 2015 · Poly E 200 mg BID · Adults aged 18 years or older with Barrett's esophagus, with or without low-grade dysplasia | 400 mg | 26 weeks | 6 |
| Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer 2012 · Poly E 800 mg EGCG dose level · Women aged 21–65 with a history of resected stage I–III hormone receptor-negative breast cancer and no evidence of disease | 1.6 g | 26 weeks | 3 |
| Novel combined single dose anti-hepatitis C therapy: a pilot study 2021 · Arm 2: Catvira · Adults over 18 with chronic genotype 4 hepatitis C, non-cirrhotic and DAA-naïve; treatment-naïve or treatment-experienced | 400 mg | 24 weeks | 40 |
| Tea-induced improvement of endothelial function in humans: No role for epigallocatechin gallate (EGCG) 2017 · Isolated EGCG · Healthy men aged 20–50 years without chronic disease or stated cardiovascular risk factors | 214 mg | 1 day | 50 |
| Assessing the analgesic efficacy of oral epigallocatechin-3-gallate on epidural catheter analgesia in patients after surgical stabilisation of multiple rib fractures: a prospective double-blind, placebo-controlled clinical trial 2020 · EGCG group · Adults aged 18 or older with multiple rib fractures and intractable pain after surgical stabilisation of rib fractures | 200 mg | 10 days | 49 |
| Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial 2016 · EGCG and cognitive training group · Adults aged 16–34 years with Down's syndrome | 9 mg/kg | 1 year | 43 |
| Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease 2007 · EGCG · Adults with coronary artery disease; age range and sex are not specified for the enrolled cohort. | 300 mg | 2 weeks | 42 |
| 'Benifuuki' green tea containing o-methylated catechin reduces symptoms of Japanese cedar pollinosis: a randomized, double-blind, placebo-controlled trial 2014 · 'Benifuuki' green tea · Adults with Japanese cedar pollinosis | 700 mL | 120 days | 26 |
| Acute Epigallocatechin 3 Gallate (EGCG) Supplementation Delays Gastric Emptying in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Crossover Study 2018 · EGCG group · Healthy young adult women, mean age 24.41 years; no stated disease or nutrient deficiency | 752 mg | 1 day | 22 |
| Epigallocatechin-3-gallate increases maximal oxygen uptake in adult humans 2010 · EGCG · Healthy adult males and females, mean age 26 ± 2 years | 405 mg | 2 days | 19 |
| Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial 2015 · EGCG · Adults with relapsing-remitting multiple sclerosis, expanded disability status scale score <4.5, receiving glatiramer acetate; 8 of 18 participants were men | 600 mg | 12 weeks | 18 |
| Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions 2003 · EGCG capsule · Patients with HPV-infected cervical lesions, including chronic cervicitis and mild, moderate or severe dysplasia; age and sex not specified | 200 mg | 12 weeks | 10 |
| A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis 2013 · 400 mg total EGCG daily · Patients with mild to moderate ulcerative colitis | 400 mg | 8 weeks | — |
| A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis 2013 · 800 mg total EGCG daily · Patients with mild to moderate ulcerative colitis | 800 mg | 8 weeks | — |
| Administration of a dietary supplement ( N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial 2009 · treatment group · Healthy overweight women and men; age not stated | 100 mg | 60 days | 71 |
| The combined effect of green tea and α-glucosyl hesperidin in preventing obesity: a randomized placebo-controlled clinical trial 2021 · GT-gH group · Healthy Japanese men and women aged 30–75 years with BMI 23–30 kg/m² and LDL cholesterol 100–140 mg/dL; not regular green tea consumers | 146 mg | 12 weeks | 30 |
| Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects 2014 · E+R · Healthy overweight women and men, mean age 35 years | 282 mg | 3 days | 18 |
| Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects 2014 · E+R+S · Healthy overweight women and men, mean age 35 years | 282 mg | 3 days | 18 |
| The effects of polyphenol supplementation on adipose tissue morphology and gene expression in overweight and obese humans 2018 · EGCG+RES · Overweight and obese men and premenopausal women; ages not specified | 282 mg | 12 weeks | 11 |
| Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans 1999 · green tea extract · 10 healthy men | 270 mg | 1 day | 10 |
| Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation 2005 · green tea-caffeine mixture · Overweight and moderately obese adults after body weight loss; matched for sex, age, BMI, height, body mass, and habitual caffeine intake | 270 mg | 90 days | — |
| Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men 2005 · 90 mg EGCG mixture · men; age and health condition not stated | 270 mg | 1 day | — |
| Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men 2005 · 200 mg EGCG mixture · men; age and health condition not stated | 600 mg | 1 day | — |
| Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men 2005 · 300 mg EGCG mixture · men; age and health condition not stated | 900 mg | 1 day | — |
| Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men 2005 · 400 mg EGCG mixture · men; age and health condition not stated | 1.2 g | 1 day | — |
| Green tea catechin plus caffeine supplementation to a high-protein diet has no additional effect on body weight maintenance after weight loss 2009 · adequate-protein diet plus green tea-caffeine mixture · Overweight and moderately obese adults, mean age 44 years, following weight loss | 270 mg | 90 days | — |
| Green tea catechin plus caffeine supplementation to a high-protein diet has no additional effect on body weight maintenance after weight loss 2009 · high-protein diet plus green tea-caffeine mixture · Overweight and moderately obese adults, mean age 44 years, following weight loss | 270 mg | 90 days | — |
| Does supplementation with green tea extract improve acne in post-adolescent women? A randomized, double-blind, and placebo-controlled clinical trial 2016 · decaffeinated green tea extract group · Women aged 25–45 years with moderate-to-severe post-adolescent acne | 856 mg | 4 weeks | — |
| Possible Reduction of Cardiac Risk after Supplementation with Epigallocatechin Gallate and Increase of Ketone Bodies in the Blood in Patients with Multiple Sclerosis. A Pilot Study 2020 · intervention group · Adults over 18 with multiple sclerosis, treated with glatiramer acetate and interferon beta, able to move without a wheelchair or walker | 800 mg | 120 days | — |
| A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study) 2025 · MLI+EGCG, participants weighing 50 kg or less · Adults aged 60–80 with subjective cognitive decline who carried APOE-ε4 and had normal-range cognitive performance | 300 mg | 1 year | — |
| A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study) 2025 · MLI+EGCG, participants weighing more than 50 kg · Adults aged 60–80 with subjective cognitive decline who carried APOE-ε4 and had normal-range cognitive performance | 500 mg | 1 year | — |
| Epigallocatechin gallate enhances sympathetic heart rate variability and decreases blood pressure in obese subjects: a randomized control trial 2024 · EGCG group · Thai adults over 18 years with obesity (BMI ≥25 kg/m²); men and women | 300 mg | 8 weeks | 15 |
| Improvement in insulin resistance and favourable changes in plasma inflammatory adipokines after weight loss associated with two months' consumption of a combination of bioactive food ingredients in overweight subjects 2013 · dietary supplement group · Healthy overweight men and women aged 25–45 years with BMI greater than 25 and less than 35 kg/m² | 300 mg | 8 weeks | 50 |
| A Randomized, Placebo-Controlled Study on the Safety and Efficacy of Daily Ingestion of Green Tea (Camellia sinensis L.) cv. "Yabukita" and "Sunrouge" on Eyestrain and Blood Pressure in Healthy Adults 2018 · Sunrouge group · Japanese adults aged 21–55 years with slightly elevated blood pressure | 324 mg | 12 weeks | 39 |
| A Randomized, Placebo-Controlled Study on the Safety and Efficacy of Daily Ingestion of Green Tea (Camellia sinensis L.) cv. "Yabukita" and "Sunrouge" on Eyestrain and Blood Pressure in Healthy Adults 2018 · Yabukita group · Japanese adults aged 21–55 years with slightly elevated blood pressure | 322 mg | 12 weeks | 38 |
| Epigallocatechin gallate (EGCG) (TEAVIGO) does not impair nonhaem-iron absorption in man 2005 · 150 mg EGCG · Healthy women with low iron stores | 150 mg | 8 days | 30 |
| Epigallocatechin gallate (EGCG) (TEAVIGO) does not impair nonhaem-iron absorption in man 2005 · 300 mg EGCG · Healthy women with low iron stores | 300 mg | 8 days | 30 |
| Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals 2005 · 400 mg dose group · healthy volunteers | 400 mg | 1 day | 10 |
| Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals 2005 · 800 mg dose group · healthy volunteers | 800 mg | 1 day | 10 |
| Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals 2005 · 1,200 mg dose group · healthy volunteers | 1.2 g | 1 day | 10 |
| A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers 2017 · low-dose Polyphenon E · Adults aged 18 years or older with a bladder tumor; men and women | 800 mg | 4 weeks | 10 |
| A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers 2017 · high-dose Polyphenon E · Adults aged 18 years or older with a bladder tumor; men and women | 1.2 g | 4 weeks | 10 |
| A single ascending dose study of epigallocatechin gallate in healthy volunteers 2003 · 50 mg EGCG group · healthy male volunteers | 50 mg | 1 day | 8 |
| A single ascending dose study of epigallocatechin gallate in healthy volunteers 2003 · 100 mg EGCG group · healthy male volunteers | 100 mg | 1 day | 8 |
| A single ascending dose study of epigallocatechin gallate in healthy volunteers 2003 · 200 mg EGCG group · healthy male volunteers | 200 mg | 1 day | 8 |
| A single ascending dose study of epigallocatechin gallate in healthy volunteers 2003 · 400 mg EGCG group · healthy male volunteers | 400 mg | 1 day | 8 |
| A single ascending dose study of epigallocatechin gallate in healthy volunteers 2003 · 800 mg EGCG group · healthy male volunteers | 800 mg | 1 day | 8 |
| A single ascending dose study of epigallocatechin gallate in healthy volunteers 2003 · 1600 mg EGCG group · healthy male volunteers | 1.6 g | 1 day | 8 |
| Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E 2001 · EGCG, 200 mg dose level · Healthy subjects; age and sex not specified | 200 mg | 1 day | 5 |
| Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E 2001 · EGCG, 400 mg dose level · Healthy subjects; age and sex not specified | 400 mg | 1 day | 5 |
| Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E 2001 · EGCG, 600 mg dose level · Healthy subjects; age and sex not specified | 600 mg | 1 day | 5 |
| Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E 2001 · EGCG, 800 mg dose level · Healthy subjects; age and sex not specified | 800 mg | 1 day | 5 |
| Dietary epigallocatechin 3-gallate supplement improves maternal and neonatal treatment outcome of gestational diabetes mellitus: a double-blind randomised controlled trial 2017 · EGCG study group · Pregnant women in their third trimester with gestational diabetes mellitus | 500 mg | — | 176 |
| Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation 2012 · 135 mg EGCG · Healthy adults | 135 mg | 1 day | 27 |
| Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation 2012 · 270 mg EGCG · Healthy adults | 270 mg | 1 day | 27 |
| The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial 2016 · GTP group · Adults aged 18 years or older with type 1 or type 2 diabetes and persistent micro- or macroalbuminuria despite ACE inhibitor and/or ARB treatment | 800 mg | 12 weeks | 24 |
| Acute Epigallocatechin-3-Gallate Supplementation Alters Postprandial Lipids after a Fast-Food Meal in Healthy Young Women: A Randomized, Double-Blind, Placebo-Controlled Crossover Study 2020 · EGCG group · Healthy women aged 18–25 years | 800 mg | 1 day | 14 |
| Effects of Timing of Acute and Consecutive Catechin Ingestion on Postprandial Glucose Metabolism in Mice and Humans 2020 · morning-green tea (MGT) · Healthy young adults; 18–? years; men and women, without diagnosed diabetes or dyslipidaemia | 135 mg | 5 days | 10 |
| Effects of Timing of Acute and Consecutive Catechin Ingestion on Postprandial Glucose Metabolism in Mice and Humans 2020 · evening-green tea (EGT) · Healthy young adults; 18–? years; men and women, without diagnosed diabetes or dyslipidaemia | 135 mg | 5 days | 9 |
| Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals 2003 · 800 mg EGCG once/day · Healthy individuals with Fitzpatrick skin type II or III | 800 mg | 4 weeks | 8 |
| Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals 2003 · 400 mg EGCG twice/day · Healthy individuals with Fitzpatrick skin type II or III | 800 mg | 4 weeks | 8 |
| Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals 2003 · 800 mg EGCG as Polyphenon E once/day · Healthy individuals with Fitzpatrick skin type II or III | 800 mg | 4 weeks | 8 |
| Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals 2003 · 400 mg EGCG as Polyphenon E twice/day · Healthy individuals with Fitzpatrick skin type II or III | 800 mg | 4 weeks | 8 |
| The polyphenol epigallocatechin gallate lowers circulating catecholamine concentrations and alters lipid metabolism during graded exercise in man: a randomized cross-over study 2023 · EGCG trial · Apparently healthy men; mean age 22.3 years | 1.45 g | 1 day | 8 |
| Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation 2015 · glatiramer acetate and EGCG · Adults with relapsing-remitting multiple sclerosis receiving glatiramer acetate; age range and sex not specified | 600 mg | — | 6 |
| Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial 2009 · EGCG · Men aged 40–65 years with BMI >28 and <38, who were overweight or obese, non-diabetic, and without significant disease | 800 mg | 8 weeks | — |
| Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women 2023 · EGCG alone · Women aged 18–40 years, with or without uterine fibroids; no known liver disease or history of alcohol abuse | 720 mg | 5 weeks | — |
| Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women 2023 · EGCG + clomiphene citrate · Women aged 18–40 years, with or without uterine fibroids; no known liver disease or history of alcohol abuse | 720 mg | 5 weeks | — |
| Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women 2023 · EGCG + letrozole · Women aged 18–40 years, with or without uterine fibroids; no known liver disease or history of alcohol abuse | 720 mg | 5 weeks | — |
| Effects of green tea supplementation on elements, total antioxidants, lipids, and glucose values in the serum of obese patients 2012 · GTE group · Adults aged 30–60 with obesity (BMI ≥30 kg/m²), 23 men and 23 women across the study | 208 mg | 90 days | 23 |
| Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene 2025 · EGCG · Non-pregnant, non-lactating women aged 18–40 years, with or without uterine fibroids | 720 mg | 30 days | 12 |
| Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene 2025 · EGCG + letrozole · Non-pregnant, non-lactating women aged 18–40 years, with or without uterine fibroids | 720 mg | 30 days | 10 |
| Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene 2025 · EGCG + clomiphene · Non-pregnant, non-lactating women aged 18–40 years, with or without uterine fibroids | 720 mg | 30 days | 8 |
| The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial 2015 · GTE · Postmenopausal women aged 50–70 years with high mammographic density and no history of cancer or proliferative breast disease | 843 mg | 1 year | 538 |
| Effects of green tea catechin extract on serum lipids in postmenopausal women: a randomized, placebo-controlled clinical trial 2016 · GTE · Healthy postmenopausal women | 843 mg | 1 year | 538 |
| Green tea extract supplementation does not modify plasma concentration of F(2)-isoprostanes in women who are postmenopause: Findings from a randomized controlled trial 2023 · GTE intervention · Postmenopausal women aged 50–70 years, generally healthy and at increased breast-cancer risk due to high breast tissue density | 843 mg | 1 year | 131 |
| Green tea extract and catechol-O-methyltransferase genotype modify the post-prandial serum insulin response in a randomised trial of overweight and obese post-menopausal women 2017 · GTE · Postmenopausal women aged 50–70 years who were overweight or obese and had dense breast tissue | 843 mg | 1 year | 30 |
| Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity 2024 · EGCG+RES · Healthy men and women aged 20–50 years with overweight or obesity and normal glucose tolerance | 282 mg | 12 weeks | 20 |
| Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers 2021 · GTE phase · Healthy Japanese adults aged 21–29 years; 7 men and 5 women enrolled | 300 mg | 1 day | 10 |
| Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome 2011 · green tea · Adults with obesity and metabolic syndrome; age and sex not further specified | 440 mg | 8 weeks | — |
| Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome 2011 · green tea extracts · Adults with obesity and metabolic syndrome; age and sex not further specified | 460 mg | 8 weeks | — |
| Effect of mixed flavonoids, n-3 fatty acids, and vitamin C on oxidative stress and antioxidant capacity before and after intense cycling 2011 · QFO · Athletes; age and sex not specified | 30 mg | 17 days | — |
| Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial 2016 · EGCG+RES · Overweight and obese adults; 18 men among 38 participants, mean age 38 ± 2 years; insulin resistance is discussed, but is not specified as an inclusion criterion | 282 mg | 12 weeks | — |
| Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women 2017 · EGCG+RES · Overweight and obese men and women; mean age 37.8 years; 18 men and 19 women enrolled | 282 mg | 12 weeks | — |
| Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers 2018 · Green tea extract (GTE) · Healthy volunteers; age and sex not reported | 150 mg | 1 day | — |
| Global testing of shifts in metabolic phenotype 2018 · PP intervention · Overweight and obese adults | 282 mg | 12 weeks | — |